head and neck cancer
Investigators published early case control data in a recent preprint showing remarkable sensitivity and are now considering their best options for further validation.
CMS Designates NavDx Test for HPV-Driven Cancer as ADLT
The test received Medicare coverage in 2023 for assessing molecular residual disease in patients with a history of HPV-driven head and neck cancer.
The firm hopes that Medicare coverage will facilitate patient access to the NavDx test and spur its inclusion in practice guidelines for head and neck cancer.
HPV Tumor DNA Liquid Biopsy Test Shows Promise for Oropharyngeal Cancer Diagnosis, Surveillance
Researchers studied the accuracy of a commercial HPV tumor DNA blood test in almost 400 patients with HPV-related oropharyngeal squamous cell carcinoma.
Cofactor Quickly Moving Immunotherapy Predictive Test to Market With Data From Intermountain Spinout
Premium
Culmination Bio's 4.5 million biospecimens and longitudinal omics and clinical data may help Cofactor rapidly advance the OncoPrism assay into multiple cancer types.